Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelubiprofen - Daewon Pharmaceutical

Drug Profile

Pelubiprofen - Daewon Pharmaceutical

Alternative Names: CS 670; DW-330; DW-330SR; DW1809; DW9801; Pelubi; Pelubiprofen sustained release; RS 2131

Latest Information Update: 31 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sankyo
  • Developer Daewon Pharmaceutical; Sankyo
  • Class Analgesics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Osteoarthritis
  • Phase III Fever
  • No development reported Acute pain; Musculoskeletal pain; Rheumatoid arthritis
  • Discontinued Rheumatic disorders

Most Recent Events

  • 31 Mar 2021 No development reported - Phase-III for Acute pain in South Korea (PO) (NCT03874247)
  • 09 Sep 2020 Daewon Pharmaceutical plans a phase III trial for Dysmenorrhoea in September 2020 , (NCT04541134)
  • 08 Sep 2020 Daewon Pharmaceutical completes phase I trial in healthy volunteers in South Korea (NCT05214690)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top